229 related articles for article (PubMed ID: 11391724)
21. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
[TBL] [Abstract][Full Text] [Related]
22. Antibodies in the treatment of lymphoma.
Leonard JP
Clin Adv Hematol Oncol; 2004 Apr; 2(4):210-1. PubMed ID: 16163182
[No Abstract] [Full Text] [Related]
23. Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura.
Bengtson KL; Skinner MA; Ware RE
J Pediatr; 2003 Nov; 143(5):670-3. PubMed ID: 14615744
[TBL] [Abstract][Full Text] [Related]
24. Evans' syndrome following autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
Kamezaki K; Fukuda T; Makino S; Harada M
Clin Lab Haematol; 2004 Aug; 26(4):291-3. PubMed ID: 15279667
[TBL] [Abstract][Full Text] [Related]
25. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
Bosly A; Keating MJ; Stasi R; Bradstock K
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
[TBL] [Abstract][Full Text] [Related]
26. Management of adult idiopathic thrombocytopenic purpura.
Nakhoul IN; Kozuch P; Varma M
Clin Adv Hematol Oncol; 2006 Feb; 4(2):136-44, 153. PubMed ID: 16728922
[TBL] [Abstract][Full Text] [Related]
27. Rituximab in the management of chronic immune thrombocytopenic purpura: what is its place?
Ducassou S; Aladjidi N; Lutz P
Pediatr Blood Cancer; 2010 Apr; 54(4):632. PubMed ID: 19953650
[No Abstract] [Full Text] [Related]
28. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience.
Zhang C; Liu HF; Chen XH; Gao L; Gao L; Liu Y; Kong PY; Sun AH; Zhang X
Clin Ther; 2014 Mar; 36(3):385-8. PubMed ID: 24594069
[TBL] [Abstract][Full Text] [Related]
29. Refractory idiopathic thrombocytopenic purpura treated with the soluble tumor necrosis factor receptor etanercept.
Litton G
Am J Hematol; 2008 Apr; 83(4):344. PubMed ID: 18186526
[No Abstract] [Full Text] [Related]
30. Elevation of activated platelet-dependent chemokines in patients with anti-CD20 monoclonal antibody (rituximab)-treated non-Hodgkin's lymphoma.
Nomura S; Ishii K; Kamitsuji Y; Uoshima N; Ishikawa E; Kitayama H; Hayashi K
Clin Appl Thromb Hemost; 2007 Apr; 13(2):206-12. PubMed ID: 17456632
[TBL] [Abstract][Full Text] [Related]
31. [Rituximab resistance in B-cell lymphoma and its elimination].
Hatake K; Terui Y
Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
[TBL] [Abstract][Full Text] [Related]
32. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
Schweizer C; Reu FJ; Ho AD; Hensel M
Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
[TBL] [Abstract][Full Text] [Related]
33. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
King KM; Younes A
Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
[TBL] [Abstract][Full Text] [Related]
34. [New treatment methods for autoimmune thrombocytopenia].
Koene HR
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2609-14. PubMed ID: 18161261
[TBL] [Abstract][Full Text] [Related]
35. [Immune thrombocytopenic purpura: pathophysiology and treatment].
Godeau B
Transfus Clin Biol; 2009 May; 16(2):101-5. PubMed ID: 19409827
[TBL] [Abstract][Full Text] [Related]
36. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
37. Pulsed dexamethasone for refractory idiopathic thrombocytopenic purpura.
Jantunen E; Nousiainen T
Am J Hematol; 1996 Dec; 53(4):281-2. PubMed ID: 8948677
[No Abstract] [Full Text] [Related]
38. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.
Maloney DG
J Clin Oncol; 2005 Sep; 23(26):6421-8. PubMed ID: 16155029
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP).
Gómez-Almaguer D
Hematology; 2012 Apr; 17 Suppl 1():S25-7. PubMed ID: 22507772
[TBL] [Abstract][Full Text] [Related]
40. New treatment options for immune-mediated hematological disorders.
Dierickx D; De Rycke A; Vanderschueren S; Delannoy A
Eur J Intern Med; 2008 Dec; 19(8):579-86. PubMed ID: 19046722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
